Omicia Wins $788K NHGRI Grant to Refine Disease Marker Annotation System | GenomeWeb
NEW YORK (GenomeWeb News) — Omicia has been awarded a $788,517 Phase II Small Business Innovation Research grant from the National Human Genome Research Institute to help it refine its disease marker genome-annotation system, the firm said today.
 
According to Omicia, the goal of the project is  to “facilitate the development of diagnostic profiles for a diverse array of disease conditions.”
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.